Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.66 |
| ▸ | HTR3B | O95264 | 5/20 | 0.66 |
| ▸ | HTR3A | P46098 | 5/20 | 0.66 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.66 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373736 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6305165 | 0.94 | CHRNA7 (0.88) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6881216 | 0.90 | CHRNA7 (0.81) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6873009 | 0.89 | CHRNA7 (0.80) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7607972 | 0.89 | CHRNA7 (0.80) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6881399 | 0.89 | CHRNA7 (0.80) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL372855 | 0.89 | CHRNA7 (0.85) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6882647 | 0.89 | CHRNA7 (0.80) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6881253 | 0.88 | CHRNA7 (0.79) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3225472 | 0.88 | CHRNA7 (0.78) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158649-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158649-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8143272-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143272-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8124620-B2 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124620-B2 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100152232-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152232-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152233-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152233-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7425561-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425561-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152233-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885HTR3E 588/4885HTR3B 336/4885 |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3E 649/4885HTR3B 380/4885 |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | CHRNA7, CHRNA1, CHRNA3 | CHRNA7 1/4885HTR3E 535/4885HTR3B 335/4885 |
| US-20100152232-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885HTR3E 588/4885HTR3B 336/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | CHRNA7 1/4885HTR3E 733/4885HTR3B 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.